A Study of Apabetalone in Subjects With Long -COVID
Status:
RECRUITING
Trial end date:
2026-03-30
Target enrollment:
Participant gender:
Summary
This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis.